“
TL;DR
The integrated model, combining a 9-metabolite signature with clinical factors, showed better performance in predicting progression-free survival than a model based on conventional clinical data alone.
Life · 12 authors, 6 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The integrated model, combining a 9-metabolite signature with clinical factors, showed better performance in predicting progression-free survival than a model based on conventional clinical data alone.
Serum samples were analyzed with widely targeted metabolomics to identify a 9-metabolite signature associated with progression-free survival (PFS). A Met score derived from this signature was integrated with clinical factors (sex, overall stage, pretreatment EBV-DNA) into a nomogram. The study limitations include its single-institution origin in an endemic area, the need for external validation, and the requirement for further investigation into the biological mechanisms of the identified metabolites.